MHRA tightens antidepressant safety communication after major review
The MHRA is moving to change how antidepressant risks are presented to patients, carers, and clinicians in the UK. The regulatory shift follows an extensive review led by the Commission on Human Medicines after concerns from patients and families about two issues that can be difficult to communicate clearly in routine practice: suicidal thoughts and behaviours, and sexual dysfunction that persists after treatment stops.
The agency is not withdrawing these medicines. It is changing the way their risks are explained.
That distinction matters in the consulting room, where antidepressants remain widely used and where patients need enough clarity to recognize rare but important harms without being pushed away from treatment that can be effective when appropriately prescribed and monitored.
New boxed warning and patient card aim to make risk information easier to find
A central change will place a new boxed warning in patient information leaflets directing attention to information on suicidal thoughts and behaviours. The practical goal is simple: make the warning harder to miss and easier to act on. A new patient card is also expected to be included in or on the medicine box, giving patients and carers a quick reminder of key safety points and when to seek further help.
This is a communications intervention as much as a regulatory one. In day-to-day care, important safety information can get lost in dense leaflet text, especially when patients are newly diagnosed, distressed, or overwhelmed by the logistics of treatment. By moving the warning to a more visible location, the MHRA is trying to increase the chance that risk discussions happen early and are remembered later.
Dr Alison Cave, the MHRA chief safety officer, framed the update around informed decision-making and clearer conversations between patients and healthcare professionals. She also emphasized a point clinicians repeat often but patients may still need to hear plainly: antidepressants are effective medicines for depression and other conditions, and for most people the benefits outweigh the risks when used under clinical supervision.
Stopping treatment abruptly without professional advice can create its own problems. Withdrawal symptoms, relapse of depression, and loss of continuity in care can all follow if the medication is discontinued suddenly in response to alarm rather than a structured review.
PSSD moves into official patient information
The other major change concerns Post SSRI Sexual Dysfunction, or PSSD. Patient information leaflets for certain antidepressants will include the term to explain the possibility that sexual symptoms may continue after treatment stops.
This is a notable regulatory acknowledgement of patient-reported experience. Sexual side effects during antidepressant therapy have long been recognized, but persistent symptoms after discontinuation have often been harder for patients to have reflected in formal medicine information. By updating the language, the MHRA is aiming to better align the leaflet with lived experience and with existing safety information.
A one-sentence reality sits underneath the policy change: patients cannot weigh a risk they are not told how to name.
The update does not mean every patient taking an antidepressant will develop persistent dysfunction. It does mean the possibility will be more visible in official materials, which should help clinicians document symptoms earlier and encourage patients to return for review rather than assuming they are alone or that nothing can be done.
Ancillary leaflet planned for first appointments and ongoing treatment
The MHRA is also developing a supporting safety leaflet with the wider healthcare system. It will be handed to patients at their first appointment discussing antidepressants and will describe the key risks and benefits to support treatment decisions. The same leaflet will also be provided to people already receiving antidepressants. Availability is expected in 2027.
That approach reaches beyond the pharmacy counter and into the start of treatment, where expectation-setting is often most useful. A structured leaflet at the first appointment can reinforce verbal counselling, give family members something concrete to review at home, and provide a reference point if side effects arise later. It may also help normalize follow-up conversations about suicidality, sexual function, adherence, and dose changes, all of which are clinically relevant and often under-discussed.
Chris Bird, programme manager for patient safety at NICE, said the review will help ensure that patients and healthcare professionals have up-to-date information for treatment decisions and support. NICE colleagues participated in the expert working group, and NICE will review its recommendations if the MHRA safety advice affects published guidance.
Regulatory alignment may reshape prescribing resources and guidance
The MHRA said it will continue working with partners across the healthcare system to support more consistent communication of antidepressant risks. That includes updates to prescribing resources, clinical guidance, and patient information materials.
For prescribers, the likely effect is not a wholesale change in therapeutic practice but a more explicit structure for counseling and follow-up. Antidepressants are used across depression and other conditions, and the safety conversation now needs to be anchored in materials that are easier to find, easier to understand, and harder to overlook. For pharmacists, nurses, and primary care clinicians, the revised leaflets and patient card may also provide a more standardized script for discussing warning signs and documenting advice.
The MHRA also points patients who suspect a side effect toward speaking with a trusted healthcare professional and reporting the reaction through the Yellow Card scheme. That reporting route matters because post-marketing pharmacovigilance depends on real-world experience, especially for adverse effects that may not be fully captured in pre-approval trials or may emerge more clearly once medicines are used at scale over longer periods.
The public assessment report has been published alongside the updated safety information, giving clinicians and patients a formal record of the review process. For practice, the immediate consequence is straightforward: antidepressant counseling in the UK is about to include more visible warnings, a new patient card, and official language on persistent sexual dysfunction, all built around the same clinical aim—safer, clearer conversations before and during treatment.